These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 23918833)

  • 1. Subtype-specific MEK-PI3 kinase feedback as a therapeutic target in pancreatic adenocarcinoma.
    Mirzoeva OK; Collisson EA; Schaefer PM; Hann B; Hom YK; Ko AH; Korn WM
    Mol Cancer Ther; 2013 Oct; 12(10):2213-25. PubMed ID: 23918833
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PIK3CA mutation uncouples tumor growth and cyclin D1 regulation from MEK/ERK and mutant KRAS signaling.
    Halilovic E; She QB; Ye Q; Pagliarini R; Sellers WR; Solit DB; Rosen N
    Cancer Res; 2010 Sep; 70(17):6804-14. PubMed ID: 20699365
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ZEB1 sensitizes lung adenocarcinoma to metastasis suppression by PI3K antagonism.
    Yang Y; Ahn YH; Chen Y; Tan X; Guo L; Gibbons DL; Ungewiss C; Peng DH; Liu X; Lin SH; Thilaganathan N; Wistuba II; Rodriguez-Canales J; McLendon G; Creighton CJ; Kurie JM
    J Clin Invest; 2014 Jun; 124(6):2696-708. PubMed ID: 24762440
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oncogenic KRAS activates hedgehog signaling pathway in pancreatic cancer cells.
    Ji Z; Mei FC; Xie J; Cheng X
    J Biol Chem; 2007 May; 282(19):14048-55. PubMed ID: 17353198
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synergistic effect between erlotinib and MEK inhibitors in KRAS wild-type human pancreatic cancer cells.
    Diep CH; Munoz RM; Choudhary A; Von Hoff DD; Han H
    Clin Cancer Res; 2011 May; 17(9):2744-56. PubMed ID: 21385921
    [TBL] [Abstract][Full Text] [Related]  

  • 6. KRAS mutational subtype and copy number predict in vitro response of human pancreatic cancer cell lines to MEK inhibition.
    Hamidi H; Lu M; Chau K; Anderson L; Fejzo M; Ginther C; Linnartz R; Zubel A; Slamon DJ; Finn RS
    Br J Cancer; 2014 Oct; 111(9):1788-801. PubMed ID: 25167228
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers.
    Ebi H; Corcoran RB; Singh A; Chen Z; Song Y; Lifshits E; Ryan DP; Meyerhardt JA; Benes C; Settleman J; Wong KK; Cantley LC; Engelman JA
    J Clin Invest; 2011 Nov; 121(11):4311-21. PubMed ID: 21985784
    [TBL] [Abstract][Full Text] [Related]  

  • 8. K-RAS mutant pancreatic tumors show higher sensitivity to MEK than to PI3K inhibition in vivo.
    Hofmann I; Weiss A; Elain G; Schwaederle M; Sterker D; Romanet V; Schmelzle T; Lai A; Brachmann SM; Bentires-Alj M; Roberts TM; Sellers WR; Hofmann F; Maira SM
    PLoS One; 2012; 7(8):e44146. PubMed ID: 22952903
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DCAMKL-1 regulates epithelial-mesenchymal transition in human pancreatic cells through a miR-200a-dependent mechanism.
    Sureban SM; May R; Lightfoot SA; Hoskins AB; Lerner M; Brackett DJ; Postier RG; Ramanujam R; Mohammed A; Rao CV; Wyche JH; Anant S; Houchen CW
    Cancer Res; 2011 Mar; 71(6):2328-38. PubMed ID: 21285251
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TRPS1 targeting by miR-221/222 promotes the epithelial-to-mesenchymal transition in breast cancer.
    Stinson S; Lackner MR; Adai AT; Yu N; Kim HJ; O'Brien C; Spoerke J; Jhunjhunwala S; Boyd Z; Januario T; Newman RJ; Yue P; Bourgon R; Modrusan Z; Stern HM; Warming S; de Sauvage FJ; Amler L; Yeh RF; Dornan D
    Sci Signal; 2011 Jun; 4(177):ra41. PubMed ID: 21673316
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ZEB1 suppression sensitizes KRAS mutant cancers to MEK inhibition by an IL17RD-dependent mechanism.
    Peng DH; Kundu ST; Fradette JJ; Diao L; Tong P; Byers LA; Wang J; Canales JR; Villalobos PA; Mino B; Yang Y; Minelli R; Peoples MD; Bristow CA; Heffernan TP; Carugo A; Wistuba II; Gibbons DL
    Sci Transl Med; 2019 Mar; 11(483):. PubMed ID: 30867319
    [TBL] [Abstract][Full Text] [Related]  

  • 12. KRAS(G12D)- and BRAF(V600E)-induced transformation of murine pancreatic epithelial cells requires MEK/ERK-stimulated IGF1R signaling.
    Appleman VA; Ahronian LG; Cai J; Klimstra DS; Lewis BC
    Mol Cancer Res; 2012 Sep; 10(9):1228-39. PubMed ID: 22871572
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Receptor tyrosine kinase-dependent PI3K activation is an escape mechanism to vertical suppression of the EGFR/RAS/MAPK pathway in KRAS-mutated human colorectal cancer cell lines.
    Vitiello PP; Cardone C; Martini G; Ciardiello D; Belli V; Matrone N; Barra G; Napolitano S; Della Corte C; Turano M; Furia M; Troiani T; Morgillo F; De Vita F; Ciardiello F; Martinelli E
    J Exp Clin Cancer Res; 2019 Jan; 38(1):41. PubMed ID: 30691487
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A subset of metastatic pancreatic ductal adenocarcinomas depends quantitatively on oncogenic Kras/Mek/Erk-induced hyperactive mTOR signalling.
    Kong B; Wu W; Cheng T; Schlitter AM; Qian C; Bruns P; Jian Z; Jäger C; Regel I; Raulefs S; Behler N; Irmler M; Beckers J; Friess H; Erkan M; Siveke JT; Tannapfel A; Hahn SA; Theis FJ; Esposito I; Kleeff J; Michalski CW
    Gut; 2016 Apr; 65(4):647-57. PubMed ID: 25601637
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Membrane-bound heparin-binding epidermal growth factor like growth factor regulates E-cadherin expression in pancreatic carcinoma cells.
    Wang F; Sloss C; Zhang X; Lee SW; Cusack JC
    Cancer Res; 2007 Sep; 67(18):8486-93. PubMed ID: 17875687
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Zeb1 in Stromal Myofibroblasts Promotes
    Sangrador I; Molero X; Campbell F; Franch-Expósito S; Rovira-Rigau M; Samper E; Domínguez-Fraile M; Fillat C; Castells A; Vaquero EC
    Cancer Res; 2018 May; 78(10):2624-2637. PubMed ID: 29490942
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutant KRAS is a druggable target for pancreatic cancer.
    Zorde Khvalevsky E; Gabai R; Rachmut IH; Horwitz E; Brunschwig Z; Orbach A; Shemi A; Golan T; Domb AJ; Yavin E; Giladi H; Rivkin L; Simerzin A; Eliakim R; Khalaileh A; Hubert A; Lahav M; Kopelman Y; Goldin E; Dancour A; Hants Y; Arbel-Alon S; Abramovitch R; Shemi A; Galun E
    Proc Natl Acad Sci U S A; 2013 Dec; 110(51):20723-8. PubMed ID: 24297898
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EGF receptor is required for KRAS-induced pancreatic tumorigenesis.
    Ardito CM; Grüner BM; Takeuchi KK; Lubeseder-Martellato C; Teichmann N; Mazur PK; Delgiorno KE; Carpenter ES; Halbrook CJ; Hall JC; Pal D; Briel T; Herner A; Trajkovic-Arsic M; Sipos B; Liou GY; Storz P; Murray NR; Threadgill DW; Sibilia M; Washington MK; Wilson CL; Schmid RM; Raines EW; Crawford HC; Siveke JT
    Cancer Cell; 2012 Sep; 22(3):304-17. PubMed ID: 22975374
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A central role for RAF→MEK→ERK signaling in the genesis of pancreatic ductal adenocarcinoma.
    Collisson EA; Trejo CL; Silva JM; Gu S; Korkola JE; Heiser LM; Charles RP; Rabinovich BA; Hann B; Dankort D; Spellman PT; Phillips WA; Gray JW; McMahon M
    Cancer Discov; 2012 Aug; 2(8):685-93. PubMed ID: 22628411
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BYL719, a selective inhibitor of phosphoinositide 3-Kinase α, enhances the effect of selumetinib (AZD6244, ARRY-142886) in KRAS-mutant non-small cell lung cancer.
    Ku BM; Jho EH; Bae YH; Sun JM; Ahn JS; Park K; Ahn MJ
    Invest New Drugs; 2015 Feb; 33(1):12-21. PubMed ID: 25342139
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.